SGLT2 Inhibitors in Elderly and Frail CKM Patients Consistent benefit across age and frailty, with no excess hypoglycaemia. d. 2026;4(15):28-29. Accessed September 17, 2026. https://www.thediabzen.com/index.php/d/article/view/57